Drug maker Lupin on Wednesday said it has launched the generic version of Oracea capsules in the US market.
The company said it has launched the medication, indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea, following approval from the US Food and Drug Administration (USFDA).
As per the IQVIA MAT data, Doxycycline capsules (Oracea) had estimated annual sales of USD 128 million in the US.
Shares of the company were trading 0.77 per cent up at Rs 1,617.35 apiece on the BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
